Selection of lead candidate from initial short-list of 6 DMT-analogues Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical […]
Databank to focus on mRNA neuroinflammatory markers and serotonin neuro-transmitters VANCOUVER, BC, April 28, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases […]
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor […]
29% increase in Twirla cycles27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022– Agile Therapeutics, Inc. (NASDAQ: AGRX), a women’s healthcare company, today announced Twirla prescription data for the first quarter […]
atai Life Sciences N.V. (NASDAQ: ATAI) Q4 2021 Earnings Highlights CEO Florian Brand: “…2021 was a truly transformative year for atai. We made important progress across our programs, expanded our diverse pipeline with multiple shots […]
— Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due to Overwhelming Evidence of Efficacy — […]
Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft […]
Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April 11, 2022 — Diffusion Pharmaceuticals Inc. (NASDAQ: […]
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated […]
Manufacturing Contract with the Toronto Institute of Pharmaceutical Technology VANCOUVER, BC, April 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]
Committed to the ‘pipeline-in-a-pill’ approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive data for recently conducted prostate cancer model and evaluates […]
Additionally, data associated with the GeneStrat® ddPCR™ and Genestrat NGS™ blood tests will be presented at the American Association for Cancer Research (AACR) BOULDER, Colo., March 29, 2022–Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with […]
VANCOUVER, BC, March 23, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce […]
VANCOUVER, BC, Feb. 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
